Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
Neuroscience
Evotec Reports Q1 2024 Results and Provides Corporate Update
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTERSTRONG START WITH JUST - EVOTEC...
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to...
King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia
King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia King Faisal Specialist Hospital & Research...
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
Curia & Carterra Biologics Symposium Biologics symposium slated for May 31 in Seattle, WA ALBANY, N.Y. and SALT LAKE CITY,...
Zeto Announces Expert Jury for Its EEG Clinical Trial Sponsorship Program
The selected clinical research projects will be publicly announced by June 10th, 2024SANTA CLARA, CA / ACCESSWIRE / May 7,...
Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities...
Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has...
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May...
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,...
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates...
BayCare’s St. Joseph’s Hospital Opens Season’s Café with Amazon’s Just Walk Out Technology
TAMPA, Fla., April 24, 2024 /PRNewswire/ -- St. Joseph's Hospital today announced that it becomes the first health care facility...
Quickcharge and Amazon Just Walk Out technology power hospital café, enabling employees to pay by badge
Expedited checkout requires limited staff overnight, enabling nearly 24/7 accessSCOTTSDALE, Ariz.--(BUSINESS WIRE)--Quickcharge, a dining and retail technology platform for Healthcare,...
NeuroNexus is Leveraging Bioz’s AI-Powered Citation Tools to Drive Increased Sales Conversion
PALO ALTO, CA / ACCESSWIRE / April 24, 2024 / Bioz, Inc., a Silicon Valley AI company, has partnered with...
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA...
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...